Actavis Rejects Mylan Offer [REPORT]

Generic drug maker Actavis Inc (NYSE:ACT) is reported to have spurned a $15 billion cash and stock acquisition offer from Mylan Inc. (NASDAQ:MYL). According to Bloomberg, Actavis Inc (NYSE:ACT) would decide instead to pursue talks to take over the Irish drug maker Warner Chilcott Plc (NASDAQ:WCRX). Earlier, Watson Pharmaceuticals completed its acquisition of the then Switzerland-based privately-held Actavis Group in a deal valued at about 4.25 billion euros or $5.6 billion in October. It then renamed itself Actavis, Inc. Following the Watson-Actavis deal, Actavis became the second largest global generic drug maker and the largest in the U.S. Prior to the…